Your session is about to expire
← Back to Search
lisocabtagene maraleucel for B-Cell Lymphoma
Study Summary
This trial will test a new immunotherapy drug, JCAR017, on patients with aggressive B-cell non-Hodgkin lymphoma who have relapsed from or are refractory to two lines of immunochemotherapy. The study will follow patients for up to 2 years to assess safety, PK, and efficacy of the drug.
- B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Lymphatic Diseases
- Lymphoma
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Cancer
- Tumors
- Non-Hodgkin's Lymphoma
- Immune Disorders
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 74 Patients • NCT03483103Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your bone marrow, kidneys, liver, lungs, and heart are working well.You have a type of blood cancer called B-cell NHL, and it has come back or is not responding to treatment. This includes different subtypes of B-cell NHL like diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and follicular lymphoma Grade 3B. You have already received treatment with certain medications like anthracycline and rituximab, and have tried at least two other types of treatment for DLBCL or had an autologous stem cell transplant.
- Group 1: Lisocabtagene maraleucel
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does lisocabtagene maraleucel have any harmful side effects?
"Lisocabtagene maraleucel's safety is only supported by Phase 2 clinical trial data, so it received a score of 2."
Is this clinical trial widely available in North America?
"This study is recruiting patients from 34 different centres, which are based in cities such as Wichita, Cincinnati and Salt Lake City. To limit travel-related demands, it would be best to select the site closest to your location."
What other lisocabtagene maraleucel clinical trials are available for review?
"Lisocabtagene maraleucel is currently being trialled in 8 clinical studies, none of which are Phase 3 trials. Most of the research locations for lisocabtagene maraleucel are based in Boston, Massachusetts; however, there are 299 total clinical trial sites for this medication."
How has lisocabtagene maraleucel been used to help patients in the past?
"Lisocabtagene maraleucel is often used to treat patients that have already tried 2 or more systemic therapies without success. This medication can also be prescribed to manage refractory diffuse large b cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), and follicular, grade 3b lymphoma."
What other similar research projects exist for comparison?
"Research into lisocabtagene maraleucel began in 2016. A small, initial study was conducted that year and sponsored by Juno Therapeutics. After the successful completion of this 385-patient trial, lisocabtagene maraleucel received Phase 1 drug approval. As of today, there are 8 ongoing clinical trials being conducted in 71 cities and 14 countries around the world."
How many people will be included in this clinical research project?
"This research is not actively recruiting new participants at the moment. It was first announced on 11/29/2018 with the latest update being on 7/29/2022. If you're hoping to participate in other studies, 8 trials for lisocabtagene maraleucel are presently admitting patients and 5117 clinical trials involve immune system disorders."
Are patients still being enrolled in this clinical trial?
"Unfortunately, this particular trial is no longer enrolling patients. Originally posted on November 29th, 2018, the study was last updated on July 29th, 2022. However, there are 5117 other studies currently looking for participants with immune system disorders and 8 different trials involving lisocabtagene maraleucel that are still recruiting patients."
Share this study with friends
Copy Link
Messenger